Catalyst
Slingshot members are tracking this event:
Phase 2 36-month OLE data of Patisiran in hATTR Patients with Polyneuropathy expected in late 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 26, 2017
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1022960
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Patisiran, Polyneuropathy
